Jimi’s Fight Against Bladder Cancer
I was born in Long Island, New York, and raised in Southern California, where I grew up surrounded by sunshine and the beauty of the ocean. For the past 14…
Continue Reading
Jimi’s Fight Against Bladder Cancer
A Smarter Urine Test for Bladder Cancer
As reported on Inside Precision Medicine, Researchers at Stanford have created a new urine test that helps doctors understand how well bladder cancer treatments are working. Usually, bladder cancer is…
Continue Reading
A Smarter Urine Test for Bladder Cancer
“At 44, I Thought I Was Starting Over” – Kristian’s Bladder Cancer Story
At 44 years old, I was ready to hit the reset button. In March of 2025, my partner and I stepped away from our careers. The decision wasn’t reckless, it…
Continue Reading
“At 44, I Thought I Was Starting Over” – Kristian’s Bladder Cancer Story
Bladder Cancer Treatment Landscape Shifts: ImmunityBio’s Long-Term Data Challenges Surgical Intervention Rates
ImmunityBio's latest clinical findings reveal a significant development in the ongoing battle against non-muscle-invasive bladder cancer, with three-year follow-up data suggesting that combining Anktiva with standard immunotherapy could fundamentally alter…
Continue Reading
Bladder Cancer Treatment Landscape Shifts: ImmunityBio’s Long-Term Data Challenges Surgical Intervention Rates
Danny Gereg Shares His Bladder Cancer Story
We're honored to bring you this video, shared with us by Danny Gereg, that details some of his journey living with bladder cancer. Danny has stayed resilient and positive, finding…
Continue Reading
Danny Gereg Shares His Bladder Cancer Story
How DNA Technology Can Guide Treatment in Muscle Invasive Bladder Cancer
Author's Note: Patient Worthy began following Natera following their presentation at the American College of Medical Genetics conference many years ago. Natera has been known for its advances in prenatal…
Continue Reading
How DNA Technology Can Guide Treatment in Muscle Invasive Bladder Cancer
An Overview on Bladder Cancer
Genetics: a cosmic role of the dice that plays a role in so many medical conditions, including bladder cancer. Mutations in FGFR3, PIK3CA, KDM6A, and TP53 are commonly associated with bladder cancer, but…
Continue Reading
An Overview on Bladder Cancer
Promising Advances for Advanced Bladder Cancer: DATROWAY® Plus Rilvegostomig in TROPION-PanTumor03 Trial
Initial results from the TROPION-PanTumor03 phase 2 trial, presented at the 2025 ESMO Congress, show that the combination of DATROWAY® (datopotamab deruxtecan) and rilvegostomig offers significant tumor responses and disease…
Continue Reading
Promising Advances for Advanced Bladder Cancer: DATROWAY® Plus Rilvegostomig in TROPION-PanTumor03 Trial
Advanced Head and Neck Squamous Cell Carcinoma Patients Double Survival Time
Health Canada’s recent approval of adjuvant (applied after surgery) Keytruda (pembrolizumab) in high-risk invasive cancer of the bladder saw patients remain free of cancer in double the current standard, according…
Continue Reading
Advanced Head and Neck Squamous Cell Carcinoma Patients Double Survival Time
Photo by Towfiqu barbhuiya on Unsplash
FDA Approves Balversa (Erdafitinib) for Locally Advanced or Metastatic Urothelial Carcinoma
Immunotherapy, targeted therapy, surgery, radiation, chemotherapy, intravesical treatment - oh my! These therapeutic options have all been used to treat individuals living with urothelial carcinoma. But the treatment landscape has…
Continue Reading
FDA Approves Balversa (Erdafitinib) for Locally Advanced or Metastatic Urothelial Carcinoma
source: shutterstock.com
ICYMI: TAR-200 for High-Risk Non-Muscle-Invasive Bladder Cancer Granted Breakthrough Therapy Designation
In the United States, Breakthrough Therapy designation is granted by the U.S. Food and Drug Administration (FDA) to expedite drug development and review. This designation is granted to therapies that…
Continue Reading
ICYMI: TAR-200 for High-Risk Non-Muscle-Invasive Bladder Cancer Granted Breakthrough Therapy Designation
source: shutterstock.com
Trial Results Double Survival for Some People with Advanced Bladder Cancer
Bladder cancer patients and their families have faced years, and even decades, of waiting for a breakthrough in bladder cancer treatment. For some patients, the results of two clinical…
Continue Reading
Trial Results Double Survival for Some People with Advanced Bladder Cancer
source: shutterstock
Rare Classroom: Bladder Cancer
Welcome to the Rare Classroom, a new series from Patient Worthy. Rare Classroom is designed for the curious reader who wants to get informed on some of the rarest, most…
Continue Reading
Rare Classroom: Bladder Cancer
Photo by Lucas Kapla on Unsplash
Agent Orange Exposure During Vietnam War Related to Heightened Bladder Cancer Risk
During the Vietnam War, the U.S. military sprayed a tactical herbicide called Agent Orange to defoliate forest areas. The goal was not only to destroy crops that could provide nourishment…
Continue Reading
Agent Orange Exposure During Vietnam War Related to Heightened Bladder Cancer Risk
1662222 / Pixabay
STUDY: Opdivo with Chemotherapy Improves Urothelial Carcinoma Survival Rates
Opdivo (nivolumab) is an immune checkpoint inhibitor that binds to PD-1 and contributes to cancer cell death. It has shown efficacy in treating a number of cancer types, both…
Continue Reading
STUDY: Opdivo with Chemotherapy Improves Urothelial Carcinoma Survival Rates
source: shutterstock.com
FDA Grants Accelerated Approval to Combination Treatment for Patients with Advanced or Metastatic Urothelial Carcinoma
According to reporting for Cure Today, the FDA recently granted Accelerated Approval to a combination treatment of Padcev (enfortumab vedotin-ejfv) and Keytruda (pembrolizumab) for advanced or metastatic urothelial carcinoma.…
Continue Reading
FDA Grants Accelerated Approval to Combination Treatment for Patients with Advanced or Metastatic Urothelial Carcinoma
Prostate Cancer: Exploring the Risk of Prostate Radiotherapy
Results of a recent study published in Medscape Medical News assessed the effect of treatment with radiotherapy on patients who have prostate cancer that is localized. Statistics show that…
Continue Reading
Prostate Cancer: Exploring the Risk of Prostate Radiotherapy
source: pixabay.com
New Data on MVP-S Plus Pembrolizumab for Bladder Cancer
The American Association for Cancer Research (AACR) Annual Meeting took place from April 8th until the 13th, with lots of interesting data and innovations presented by some of the leaders…
Continue Reading
New Data on MVP-S Plus Pembrolizumab for Bladder Cancer
source: shutterstock
Rare Classroom: Urothelial Carcinoma
Welcome to the Rare Classroom, a new series from Patient Worthy. Rare Classroom is designed for the curious reader who wants to get informed on some of the rarest, most…
Continue Reading
Rare Classroom: Urothelial Carcinoma
source: pixabay.com
DPX Delivery Platform Could Improve Care For Many Rare Cancers
IMV Inc. recently presented two posters at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics showcasing their DPX delivery platform's immunotherapeutic capabilities. IMV Inc. IMV Inc. is…
Continue Reading
DPX Delivery Platform Could Improve Care For Many Rare Cancers
nastya_gepp / Pixabay
Nivolumab Receives Additional Indication for Urothelial Carcinoma
Nivolumab has recently received an additional indication for the treatment of urothelial carcinoma with a high risk for recurrence following radical resection, a form of bladder cancer. This decision came…
Continue Reading
Nivolumab Receives Additional Indication for Urothelial Carcinoma
source: pixabay.com
Berzosertib Fails to Improve Urothelial Carcinoma PFS
Clinical trials are often used to understand the safety, efficacy, and tolerability of specific treatments. Unfortunately, sometimes the drugs in these studies fail. According to Targeted Oncology, this occurred in…
Continue Reading
Berzosertib Fails to Improve Urothelial Carcinoma PFS
source: pixabay.com
Non-Muscle Invasive Bladder Cancer: Adverse Events in Immunotherapy
In a story for the Urology Times, a panel of experts on the treatment of non-muscle invasive bladder cancer that is not responsive to Bacillus Calmette-Guérin (BCG) (which is commonly…
Continue Reading
Non-Muscle Invasive Bladder Cancer: Adverse Events in Immunotherapy
Source: Pixabay
EMA Validates Opdivo Application for Urothelial Carcinoma
On March 29, 2021, global biopharmaceutical company Bristol Myers Squibb ("BMS") shared that its type II variation application for Opdivo (nivolumab) was validated by the European Medicines Agency (EMA).…
Continue Reading
EMA Validates Opdivo Application for Urothelial Carcinoma
Aymanjed / Pixabay
Two sBLAs Submitted for PADCEV for Urothelial Cancer
In 2007, biotechnology company Seagen Inc. and pharmaceutical company Astellas Pharma Inc. ("Astellas") collaborated to develop enfortumab vedotin. Now, in 2021, the pair submitted two supplemental Biologics License Applications (sBLAs)…
Continue Reading
Two sBLAs Submitted for PADCEV for Urothelial Cancer
